Compound News and Research

RSS

Teva Cutting 5,000 Jobs In Global Restructuring

...

10 Oct 2013

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced today the continuation of the development program of Lu AE58054 for the treatment of Alzheimer's disease, initiating the first out of four phase III clinical trials with the compound.

10 Oct 2013

Possible topical treatment for age-related macular degeneration identified by Tufts researchers

Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration in a study of mice that shows promise for clinical use.

10 Oct 2013

Research points to causes, potential treatment approaches for systemic sclerosis

Using mice, lab-grown cells and clues from a related disorder, Johns Hopkins researchers have greatly increased understanding of the causes of systemic sclerosis, showing that a critical culprit is a defect in the way certain cells communicate with their structural scaffolding

10 Oct 2013

Olympus launches forward-viewing curvilinear ultrasound gastrovideoscope

Olympus, a precision technology leader in designing and delivering innovative solutions in the medical and surgical field, among other core businesses, announced today the launch of its 510(k) cleared and world's only forward-viewing curvilinear ultrasound gastrovideoscope.

From Evident Corporation - Life Sciences 10 Oct 2013

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

Allegro Ophthalmics, LLC, a company dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vascular eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to begin two Phase II clinical studies of ALG-1001.

10 Oct 2013

U.S. Army Grants QR Pharma, UCLA $3M To Test TBI Treatment

...

9 Oct 2013

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapeutics, announced today that it recently secured an $8.5M series C financing led by Excel Venture Management. Santé Ventures, an existing investor, also participated in the round.

9 Oct 2013

Understanding the biological players in clot formation could lead to new thrombotic therapies

Ulhas Naik, professor of biological sciences and director of the Delaware Cardiovascular Research Center, pores over laboratory data on his computer, even during breakfast most mornings. He is on a quest to tease out the roles that various blood components play in the formation of clots.

9 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

...

8 Oct 2013

Two researchers receive $2.5M grant to continue their research on cancer cell growth

A pair of researchers at Rutgers Cancer Institute of New Jersey has been awarded nearly $2.5 million dollars to further study in their respective laboratories.

8 Oct 2013

New medications may be used to treat common heart-rhythm problem

An international research team led by medical scientists at the University of Alberta has shown that new medications based on resveratrol - a compound found in red wine and nuts - may be used to treat a common heart-rhythm problem known as atrial fibrillation.

8 Oct 2013

NAC amino acid may offer new treatment options for psychiatric disorders

Improved understanding of the roles of inflammation and oxidative stress in psychiatric disorders has generated new leads in the search for novel therapies. One such investigative compound currently in clinical trials is an amino acid, N-Acetyl Cysteine (NAC), which appears to reduce the core symptoms of bipolar disorder, schizophrenia, depression, autism and cravings in addictions including cocaine, cannabis abuse and cigarette smoking.

8 Oct 2013

Scientists devised technique to make antibody-drug conjugates, basis of new therapies

Chemists at The Scripps Research Institute (TSRI) have devised a new technique for connecting drug molecules to antibodies to make advanced therapies.

8 Oct 2013

Newly discovered compound could be developed as antifungal drug to treat fungal infections

On a molecular level, you have more in common with shower curtain mold or the mushrooms on your pizza than you might think. Humans and fungi share similar proteins, a biological bond that makes curing fungal infections difficult and expensive.

7 Oct 2013

Researchers create catalyst that alters chemical profiles of numerous types of small molecules

Researchers report that they have created a man-made catalyst that is an "enzyme mimic." Unlike most enzymes, which act on a single target, the new catalyst can alter the chemical profiles of numerous types of small molecules.

7 Oct 2013

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

Investigators at The Feinstein Institute for Medical Research have discovered a protein in the human body that can trigger and mediate inflammation in patients suffering from hemorrhage and sepsis. The findings were published in the online version of Nature Medicine on October 6, 2013.

7 Oct 2013

Metabolic enzymes in opium poppy are used to produce valuable painkilling drugs

University of Calgary scientists have discovered metabolic enzymes in the opium poppy that play "widespread roles" in enabling the plant to make painkilling morphine and codeine, and other important compounds.

5 Oct 2013

Scientists identify new drug for inherited form of cancer with no known cure

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified a new drug candidate for an inherited form of cancer with no known cure.

3 Oct 2013

Compound News and Research

Teva Cutting 5,000 Jobs In Global Restructuring

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

Possible topical treatment for age-related macular degeneration identified by Tufts researchers

Research points to causes, potential treatment approaches for systemic sclerosis

Olympus launches forward-viewing curvilinear ultrasound gastrovideoscope

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

U.S. Army Grants QR Pharma, UCLA $3M To Test TBI Treatment

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Understanding the biological players in clot formation could lead to new thrombotic therapies

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

Two researchers receive $2.5M grant to continue their research on cancer cell growth

New medications may be used to treat common heart-rhythm problem

NAC amino acid may offer new treatment options for psychiatric disorders

Scientists devised technique to make antibody-drug conjugates, basis of new therapies

Newly discovered compound could be developed as antifungal drug to treat fungal infections

Researchers create catalyst that alters chemical profiles of numerous types of small molecules

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

Metabolic enzymes in opium poppy are used to produce valuable painkilling drugs

Scientists identify new drug for inherited form of cancer with no known cure

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News